| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $48.0M | +15.2% |
| SG&A Expense | $16.1M | -4.1% |
| Operating Income | -$64.1M | -9.7% |
| Net Income | -$61.0M | -14.1% |
| EPS (Basic) | -$2.04 | -8.5% |
| EPS (Diluted) | -$2.04 | -8.5% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $36.1M | -39.2% |
| Current Assets | $39.6M | -55.6% |
| Total Assets | $52.7M | -48.6% |
| Current Liabilities | $7.5M | -4.4% |
| Total Liabilities | $11.3M | -5.7% |
| Stockholders' Equity | $41.4M | -54.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$55.0M | -12.3% |
| Capital Expenditures | $85K | -75.2% |
| Investing Cash Flow | $26.4M | +262.3% |
| Financing Cash Flow | $5.3M | -81.4% |
| Free Cash Flow | -$55.1M | -11.7% |